NICE TA259: Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy). Abiraterone – a recommended option for metastatic prostate cancer after testosterone reduction therapy and docetaxel. NHSE commissioned. (Decision date - July 2012)
NICE TA387: for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NHSE commissioned. (Decision date - May 2016)
DO NOT PRESCRIBE (DNP)
NICE TA721 - Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. (Decision date - September 2021)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
